Journal article
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
Abstract
BACKGROUND: Pelareorep is an oncolytic virus with activity in many cancers including prostate. It has in vitro synergism with microtubule-targeted agents. We undertook a clinical trial evaluating pelareorep in mCRPC patients receiving docetaxel.
PATIENTS AND METHODS: In this randomized, open-label phase II study, patients received docetaxel 75mg/m2 on day 1 of a 21-day cycle and prednisone 5mg twice daily, in combination with pelareorep (arm A) …
Authors
Eigl BJ; Chi K; Tu D; Hotte SJ; Winquist E; Booth CM; Canil C; Potvin K; Gregg R; North S
Journal
Oncotarget, Vol. 9, No. 8, pp. 8155–8164
Publisher
Impact Journals
Publication Date
January 30, 2018
DOI
10.18632/oncotarget.24263
ISSN
1949-2553